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OBJECTIVE To perform patient-specific meta-analysis (MA) of two independent clinical validation studies
of a 17-gene biopsy-based genomic assay as a predictor of favorable pathology at radical prostatectomy.
MATERIALS AND
METHODS
Patient-specific MA was performed on data from 2 studies (732 patients) using the Genomic Pros-
tate Score (GPS; scale 0-100) together with Cancer of the Prostate Risk Assessment (CAPRA)
score or National Comprehensive Cancer Network (NCCN) risk group as predictors of the like-
lihood of favorable pathology (LFP). Risk profile curves associating GPS with LFP by CAPRA
score and NCCN risk group were generated. Decision curves and receiver operating character-
istic curves were calculated using patient-specific MA risk estimates.
RESULTS Patient-specific MA-generated risk profiles ensure more precise estimates of LFP with narrower
confidence intervals than either study alone. GPS added significant predictive value to each clini-
cal classifier. A model utilizing GPS and CAPRA provided the most risk discrimination. In decision-
curve analysis, greater net benefit was shown when combining GPS with each clinical classifier
compared with the classifier alone. The area under the receiver operating characteristic curve im-
proved from 0.68 to 0.73 by adding GPS to CAPRA, and 0.64 to 0.70 by adding GPS to NCCN
risk group. The proportion of patients with LFP >80% increased from 11% using NCCN risk group
alone to 23% using GPS with NCCN. Using GPS with CAPRA identified the highest
proportion—31%—of patients with LFP >80%.
CONCLUSION Patient-specific MA provides more precise risk estimates that reflect the complete body of evidence.
GPS adds predictive value to 3 widely used clinical classifiers, and identifies a larger proportion of low-
risk patients than identified by clinical risk group alone. UROLOGY 89: 69–75, 2016. © 2016 The
Authors. Published by Elsevier Inc.
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Anumber of new tissue-based molecular assayshave been developed to provide improved riskstratification for men with newly diagnosed,
clinically localized prostate cancer to help guide therapeu-
tic decisions, such as immediate definitive therapy vs active
surveillance. These prognostic assays must meet a
suitable level of clinical validation before gaining
widespread adoption into clinical urological practice.
Studies using archival specimens can provide level I evi-
dence if a suitable “prospective-retrospective” study design
is used.1
One such assay is the Oncotype DX Prostate Cancer
Assay, a biopsy-based test that measures the expression of
17 genes (12 cancer-related and 5 reference) to provide a
Genomic Prostate Score (GPS; scaled 0-100) as a measure
of biologic aggressiveness. Two “prospective-retrospective”
clinical studies have validated GPS as a strong and inde-
pendent predictor of adverse pathology (AP) at radical pros-
tatectomy (RP), thus, providing level I evidence.2,3
Using GPS together with National Comprehensive
Cancer Network (NCCN) clinical risk group, the test cur-
rently provides an estimate of the likelihood of favorable
pathology (LFP), which is furnished in the patient report
of a commercial-grade assay, based on data from the first
validation study. The second validation study confirmed
the association between GPS and LFP. Although the base-
line characteristics of both cohorts were similar, there were
some differences, including the inclusion criteria for in-
termediate risk patients, the percentage of African Ameri-
can patients, and the pathologist responsible for the central
pathology review. To provide more broadly representa-
tive and precise estimates of LFP, we combined informa-
tion from both studies and examined predictive models using
GPS with other clinical risk-stratifying tools.
To take full advantage of the combined data from these
studies, which comprise a total of 732 patients, a patient-
specific meta-analysis (MA) was performed.4 Patient-
specific MA combines predictions for individual patients
from multiple studies, with weighting based on the preci-
sion of each prediction, thereby permitting more precise
risk estimates with narrower confidence intervals that reflect
the complete body of evidence collected across these
studies.4 Patient-specific MA was applied previously to the
prognostic information provided by Oncotype DX Breast
Cancer Assay Recurrence Score together with pathology
and clinical covariates in 2 studies of early stage breast
cancer.5 An educational tool providing estimates of distant
recurrence risk of breast cancer based on the patient-
specific MA calculation is available online.
Using the patient-specific MA, we sought (1) to deter-
mine if GPS added predictive value to 3 widely used clini-
cal risk stratification tools (Cancer of the Prostate Risk
Assessment [CAPRA] score, NCCN risk group, and Ameri-
can Urology Association/European Association of Urology
[AUA/EAU] risk group), and (2) to provide a better es-
timate of the proportion of patients identified for whom
the risk of aggressive disease is very low than is identified
by clinical risk group alone.
MATERIALS AND METHODS
Patients and Study Design
The patient selection criteria and study design for the Univer-
sity of California San Francisco (UCSF) and the Uniformed Ser-
vices University Center for Prostate Disease Research (CPDR)
clinical validation studies of GPS have been described previously.2,3
Both studies included patients who were potential candidates for
active surveillance under relatively broad inclusion criteria at
diagnosis—(ie, biopsy Gleason score [GS] 3 + 3 or 3 + 4 disease
[Gleason 4 + 3 disease was permitted in the CPDR study]),
prostate-specific antigen (PSA) ≤20, and clinical stage ≤T2—but
who elected RP within 6 months of diagnosis. Patients were iden-
tified from the institutional review board-approved clinical da-
tabases and biobanks at each institution. The UCSF study patients
were diagnosed from 1997 to 2011 and the CPDR study pa-
tients were diagnosed from 1990 to 2011. Exclusion criteria in-
cluded any neoadjuvant therapy, <1 mm total biopsy tumor length,
missing prostatectomy or biopsy tissue for central pathology review,
and inadequate ribonucleic acid (RNA) quality for analysis. All
biopsies and prostatectomies were centrally reviewed by aca-
demic urologic pathologists (Jeffry P. Simko for UCSF study, Isabell
A. Sesterhenn for CPDR study), following the 2005 Interna-
tional Society of Urological Pathology Consensus guidelines.6 Pa-
thology review of biopsies was performed blinded to the review
of RP and vice versa. Patients from these validation studies were
excluded from the MA if they were found to have biopsy GS 4
+ 3 disease at diagnosis or pathologic pT2+ (because capsular in-
cision renders the true tumor status with regard to organ con-
finement indeterminate) at RP upon central pathology review.
GPS Assay and End Point
The Oncotype DX Prostate Cancer Assay (GPS assay) has been
described previously, and analyzes the expression levels of 17-genes
(12 cancer-related and 5 reference) to provide the GPS, which
is scaled from 0 to 100.7 The end point of AP at RP for both studies
was defined as high-grade (primary GS pattern 4 or any pattern
5) or non−organ-confined disease (pT3).7 Favorable pathology
(FP) at RP is defined as low-grade (surgical GS 3 + 3 or 3 + 4
with no pattern 5) and organ-confined disease (pT2).
Statistical Methods
The analyses performed included GPS plus each of 3 widely used
clinical risk assessment tools: CAPRA score,8 NCCN risk group,9
and AUA/EAU risk group.10,11 For each of the combinations, mul-
tivariable logistic regression models with factors for the clinical
risk assessment tool and GPS were fit separately to each study,
with AP as the end point. The CAPRA score, which ranged from
0 to 5 across the 2 study populations, was treated as a continu-
ous numerical variable in the logistic regression models. Pa-
tients classified as having clinical T2c disease were excluded from
the patient-specific MA of GPS plus AUA/EAU risk group,
because these patients are considered to have high-risk disease
using the AUA/EAU risk classification system.
Both studies enrolled patients with NCCN very low, low, and
intermediate risk disease. However, the enrollment of intermediate-
risk patients in the UCSF study was restricted to patients with
low volume (≤3 positive biopsy cores or ≤33% of positive cores)
Gleason score 3 + 4 disease2; the CPDR study enrolled all
intermediate-risk patients, regardless of tumor volume.3 The
patient-specific MAmethod can accommodate the “special popu-
lation” of NCCN intermediate-risk patients with high tumor
volume, who were included only in the CPDR study, provided
2 assumptions are met4: (1) there is no interaction between NCCN
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risk-tumor volume category and GPS in the prediction of AP,
which can be tested using the study data; and (2) if NCCN
intermediate-risk, high tumor volume patients had been in-
cluded in the UCSF study, the relation of their risk of AP to other
patients’ would have been similar to the relationship in the CPDR
study. The second assumption is not testable based on data, but
is plausible based on the characteristics of the populations of the
2 studies.
An MA likelihood ratio test was used to assess whether GPS
added predictive value for the LFP above the clinical risk assess-
ment tools by summing across studies the likelihood ratio chi-
square test statistic, comparing the full model (GPS and clinical
risk assessment tool) with the reduced model (clinical risk as-
sessment tool alone).
The LFP for a given patient with specified clinical risk group
and GPS was estimated by combining information from both
studies using fixed-effect patient-specific MA.4 Following this
method, the individual patient’s log odds of FP was first esti-
mated for each study using logistic regression models. The 2 es-
timates were then averaged, weighting by their patient-specific
inverse variances, and transformed to the probability scale to get
the LFP estimate and 95% confidence interval.
For NCCN risk group, the NCCN intermediate-risk group high
tumor volume patients in the CPDR study were handled as a
special population for the patient-specific MA because these pa-
tients were not included in the UCSF study. To obtain an overall
estimate of NCCN intermediate-risk group patients regardless of
tumor volume, a logistic regression model was fit to the CPDR
study data to estimate the probability that an NCCN intermediate-
risk patient has high tumor volume given the patient’s GPS. The
LFP for an NCCN intermediate-risk group patient with given GPS
was then estimated by averaging the LFP estimates for low tumor
volume and high tumor volume, weighting by the estimated prob-
ability of high volume.
Receiver operating characteristic (ROC) curves and deci-
sion curves12 were calculated using the patient-specific MA es-
timates of the likelihood of AP and the AP status data combined
across both studies. In these calculations, sensitivity was esti-
mated by the proportion of patients with AP who had patient-
specific MA estimate of the likelihood of AP greater than each
cutoff; specificity was estimated as the proportion of patients
without AP who had patient-specific MA estimate of the like-
lihood of AP less than or equal to each cutoff. The area under
the ROC curve (AUC) for GPS plus each clinical risk assess-
ment tool was compared with the AUC for the clinical risk as-
sessment tool alone, using the method of DeLong et al.13
RESULTS
Study Population Characteristics
A total of 732 evaluable patients contributed data to the
MA (389 from the UCSF study and 343 from the CPDR
study) (Supplemental Fig. S1). Patients were excluded from
the MA if the biopsy GS was 4 + 3 (n = 13), pathologic
T-stage at RP was pT2+ (n = 45) after central review, or
RP specimen was unavailable for central review (n = 7).
Baseline characteristics are described in Table 1 and
Supplemental Table S1. Patient age at diagnosis, PSA at
diagnosis, CAPRA score, NCCN risk groups, and AUA/
EAU risk groups were all similarly distributed in these
studies. Of note, there were more African American patients
in the CPDR cohort (20%) than in the UCSF cohort (3%).
NCCN intermediate-risk patients with biopsy GS 3 + 4 and
high volume (>3 positive biopsy cores and >33% of posi-
tive cores) were enrolled only in the CPDR study. A similar
percentage of patients had high-grade at RP (primary GS
pattern 4 or any pattern 5) in the 2 studies, whereas 6%
more patients had non−organ-confined disease in the CPDR
study than in the UCSF study. GPS ranged from 1 to 74,
with a median of 27 in both studies. Compared to either
individual study, the 2 studies collectively represent a
broader spectrum of contemporarily managed prostate cancer
patients.
Multivariable Logistic Regression Analysis
Odds ratios for AP derived from the multivariable logis-
tic regression models for the 2 studies individually are pre-
sented in Supplemental Table S2. GPS was a statistically
significant predictor of AP after adjustment of CAPRA score
or NCCN risk group or AUA/EAU risk group, in each study.
The directions of the association of GPS and the clinical
risk assessment tools with AP are the same in the 2 studies,
and the magnitudes of association are broadly consistent
with overlapping confidence intervals. The odds ratios from
the multivariable models are not significantly different
between the 2 studies (P ≥ .20). Wald tests for the inter-
action of GPS with NCCN risk group-tumor volume cat-
egory (Very Low, Low, Low-volume Intermediate and High-
volume Intermediate) were not statistically significant
(UCSF study χ2 = 2.42, 2 d.f., P = .30; CPDR study,
χ2 = 5.52, 3 d.f., P = .14; MA χ2 = 7.94, 5 d.f., P = .16).
A test specifically comparing the GPS odds ratio in NCCN
intermediate high tumor volume patients to the GPS odds
ratio in NCCN intermediate low tumor volume and other
NCCN group patients in the CPDR study also found no
evidence of interaction (χ2 = 1.06, 2 d.f., P = .30). These
tests support the validity of the patient-specific MA with
special populations (see Materials and Methods).
Likelihood ratio tests showed that GPS adds signifi-
cant predictive value for the LFP to each of the 3 clinical
risk tools—CAPRA score, NCCN risk group, and AUA/
EAU risk group—in each study individually (all P ≤ .002)
and in the MA (P < .001; Supplemental Table S3).
LFP Estimated by Patient-specific MA
Within each CAPRA score, NCCN risk group, or AUA/
EAU risk group, GPS further discriminated patients’ LFP,
yielding a wide range of LFP within each group (Fig. 1 and
Supplemental Fig. S2). Combining GPS with CAPRA score
provided the most individualized LFP estimates and the
widest range of LFP among individual patients (Fig. 1A).
Comparison of LFP From Patient-specific MA and
Individual Studies
The weighting scheme used to combine the log odds es-
timates from the 2 studies ensures that patient-specific MA
estimates of LFP are more precise than for either of the
individual studies.4 Based on the estimates of the log odds
of AP for the patients in the UCSF and CPDR studies,
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Table 1. Distribution of baseline characteristics
Characteristic
Study
UCSF
N = 389
CPDR
N = 343
All
N = 732
GPS (0-100) Median 24 30 27
Min 1 2 1
Max 65 74 74
Age at diagnosis Median 58.0 61.7 60.0
Min 38.0 40.8 38.0
Max 77.0 75.6 77.0
Race, n (%) Caucasian 354 (91.0) 260 (75.8) 614 (83.9)
African American 12 (3.1) 69 (20.1) 81 (11.1)
Other 23 (5.9) 14 (4.1) 37 (5.1)
Diagnostic PSA ng/mL, n (%) <4 79 (20.3) 80 (23.3) 159 (21.7)
4-9.99 261 (67.1) 232 (67.6) 493 (67.3)
10-20 49 (12.6) 31 (9.0) 80 (10.9)
Clinical T2 vs T1, n (%) T1 226 (58.1) 236 (68.8) 462 (63.1)
T2 163 (41.9) 107 (31.2) 270 (36.9)
Biopsy Gleason Score, n (%) ≤3 + 3 297 (76.3) 262 (76.4) 559 (76.4)
3 + 4 92 (23.7) 81 (23.6) 173 (23.6)
NCCN risk group*, n (%) Very Low 37 (9.7) 41 (12.3) 78 (10.9)
Low 189 (49.5) 186 (55.7) 375 (52.4)
Intermediate 156 (40.8) 107 (32.0) 263 (36.7)
Total 382 334 716
CAPRA†, n (%) 0 19 (4.9) 15 (4.4) 34 (4.7)
1 141 (36.3) 129 (37.9) 270 (37.0)
2 149 (38.3) 105 (30.9) 254 (34.8)
3 60 (15.4) 62 (18.2) 122 (16.7)
4 20 (5.1) 24 (7.1) 44 (6.0)
5 0 5 (1.5) 5 (0.7)
Total 389 340 729
RP Gleason Score, n (%) 3 + 3 185 (47.6) 195 (56.9) 380 (51.9)
3 + 4 135 (34.7) 80 (23.3) 215 (29.4)
Any major pattern 4 or
any pattern 5
69 (17.4) 68 (19.8) 137 (18.7)
Pathologic T-Stage, n (%) T2 308 (79.2) 252 (73.5) 560 (76.5)
T3a 70 (18.0) 77 (22.4) 147 (20.1)
T3b 11 (2.8) 14 (4.1) 25 (3.4)
CAPRA, Cancer of the Prostate Risk Assessment; CPDR, Center for Prostate Disease Research; GPS, Genomic Prostate Score; NCCN,
National Comprehensive Cancer Network; PSA, prostate-specific antigen; RP, radical prostatectomy; UCSF, University of California at
San Francisco.
* NCCN is missing for 16 patients (n = 9 from CPDR study, n = 7 from UCSF study).
† CAPRA is missing for 3 patients from CPDR study.
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Figure 1. (A) Risk profile plot by patient-specific meta-analysis with GPS plus CAPRA. (B) Risk profile plot by patient-
specific meta-analysis with GPS plus NCCN. CAPRA, Cancer of the Prostate Risk Assessment; NCCN, National Compre-
hensive Cancer Network; GPS, Genomic Prostate Score.
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patient-specific MA confidence interval widths were nar-
rower than the shortest of the confidence intervals from
the 2 studies individually—a median of 24% (range
18%-29%) using GPS and CAPRA score, 23% (range
14%-29%) using GPS and NCCN risk group, and 24%
(range 19%-29%) using GPS and AUA/EAU risk group.
The confidence intervals for LFP are asymmetric but have
similar properties, with patient-specific MA intervals being
tighter than individual study intervals. For illustration, LFP
estimates and 95% confidence intervals for hypothetical
patients based on both individual studies and the patient-
specific MA are shown in Figure 2 and Supplemental
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Figure 2. (A) Likelihood of favorable pathology for hypothetical individual patients with GPS values of 15, 30, and 45 and
different clinical risk assessment tools from the 2 validation studies and the patient-specific meta-analysis for CAPRA. (B)
Likelihood of favorable pathology for hypothetical individual patients with GPS values of 15, 30, and 45 and different clini-
cal risk assessment tools from the 2 validation studies and the patient-specific meta-analysis for NCCN. CAPRA, Cancer
of the Prostate Risk Assessment; CPDR, Center for Prostate Disease Research; GPS, Genomic Prostate Score; MA, meta-
analysis; NCCN, National Comprehensive Cancer Network; UCSF, University of California at San Francisco.
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Figure S3. Figure 2A compares the LFP estimates for hy-
pothetical patients with low (15), intermediate (30), and
high (45) GPS values using CAPRA score, whereas
Figure 2B compares the LFP estimates for the same 3 hy-
pothetical patients using the NCCN risk group popula-
tions common to the two studies (very low, low, and
intermediate with low tumor volume). The comparison of
the LFP estimates using AUA/EAU risk groups are in
Supplemental Figure S2.
Clinical Significance
The CAPRA score used alone provided the highest ROC
curve AUC among the 3 clinical risk assessment tools
(Fig. 3C and Supplemental Fig. S4). Using GPS together
with each clinical risk assessment tool significantly im-
proved the AUC compared with the clinical risk assess-
ment tool alone. AUC increased from 0.68 to 0.73 by adding
GPS to CAPRA score, from 0.64 to 0.70 by adding GPS
to NCCN risk group, and from 0.62 to 0.70 by adding GPS
to AUA/EAU risk group (all P < .001).
In decision-curve analysis (Fig. 3), greater net benefit
was shown when combining GPS with the clinical risk as-
sessment tools compared with clinical risk tools alone. Over
a wide range of threshold probabilities, incorporation of
GPS would be expected to lead to fewer treatments of pa-
tients who have FP at RP without increasing the number
of patients with AP left untreated.
As an illustration, in these 2 validation studies com-
bined, 11% of all patients were clinically classified as NCCN
very low risk, and 90% of these patients had an LFP >80%.
In comparison, the proportion of all patients with an MA-
estimated LFP >80% was 23% using GPS with NCCN.
Using GPS with CAPRA identified the largest
proportion—31%—of patients with an MA-estimated LFP
>80%.
COMMENTS
The adoption of a prognostic biomarker into clinical prac-
tice requires a substantial body of evidence, including ana-
lytical validation, clinical validation, and evidence of clinical
utility.14 Clinical validation, in particular, requires that the
assay be shown to be a strong predictor of 1 or more clini-
cally meaningful end points in multiple studies using in-
dependent patient cohorts that collectively reflect a relevant
group of patients with the disease. GPS was validated in
2 separate patient populations of men with localized pros-
tate cancer who were candidates for active surveillance as
a predictor of AP at surgery.2,3 In both studies, the assay
was a statistically significant predictor of outcome after ad-
justment for conventional clinical and pathologic features.
A major challenge of developing a refined risk predic-
tion model based on these studies was how to incorpo-
rate the data from both patient cohorts into the prediction.
Although the clinical characteristics of the 2 patient cohorts
were similar, there were nonetheless some key differences
in the representation of different racial groups and higher-
risk patients. Not surprisingly, the risk estimates for AP,
including the likelihood of high-grade and organ-confined
disease, were numerically different in the 2 studies, al-
Figure 3. Decision curves from patient-specific meta-analysis based on models of GPS plus clinical risk assessment tools:
(A) CAPRA, (B) NCCN, and (C) area under the curve (AUC) of receiver operating characteristics from patient-specific meta-
analysis. CAPRA, Cancer of the Prostate Risk Assessment; GPS, Genomic Prostate Score; NCCN, National Comprehen-
sive Cancer Network.
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though the confidence intervals overlapped. Patient-
specific MA permitted combining prediction information
derived from more than 700 patients in the 2 studies to
produce more precise risk estimates, with narrower confi-
dence intervals than either study alone.
Another key issue was whether a predictive model could
be developed that utilized different clinical risk stratifica-
tion systems—for example, CAPRA, NCCN, and AUA/
EAU—because clinicians use a variety of risk categorizations
in their practice. In each of the 2 validation studies, a pre-
dictive model that incorporated GPS and NCCN risk groups
improved risk stratification compared to NCCN risk as-
sessment alone. In this MA, it was shown that the inclu-
sion of GPS improved risk stratification for each of the 3
clinical risk tools. In addition, the level of discrimination
for risk of AP was shown to improve with increasing granu-
larity of the clinical risk tool used. GPS plus CAPRA pro-
vided better risk discrimination, followed by GPS plus
NCCN risk, then GPS plus AUA/EAU risk group. Finally,
the predictive model derived from this MA identifies a much
higher fraction of patients with a high LFP (23%
GPS +NCCN) than is identified by clinical risk group alone
(11% NCCN alone).
CONCLUSION
Use of a patient-specific MA strategy, combining predic-
tion information from 2 independent clinical validation
studies, provided a more precise risk stratification for men
with newly diagnosed, clinically localized prostate cancer,
and showed that GPS adds predictive value to each of the
3 most widely used clinical risk-stratification tools. This
new composite model should provide more individual-
ized risk prediction and permit physicians and their pa-
tients to make decisions regarding active surveillance vs
immediate treatment with greater confidence.
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APPENDIX
SUPPLEMENTARY DATA
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.urology
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